title: Effects of adequate versus inadequate treatment of cutaneous manifestations of Lyme borreliosis on the incidence of late complications and late serologic status.
abstract: Eighty-two patients who were treated at the Department of Dermatology, Innsbruck, Austria, from 1980 to 1987 for cutaneous manifestations of Lyme disease were subjected to a clinical follow-up investigation aimed at detecting dermatologic, neurologic, and internal late complications of borreliosis. Only 54 of these patients had received adequate antibiotic treatment according to current standards. Also, their sera were investigated for the presence of immunoglobulin G (IgG) and IgM Borrelia burgdorferi antibodies by an indirect immunofluorescence assay, three different enzyme-linked immunosorbent assays, and immunoblotting. As a control, the sera of 126 healthy blood donors were investigated with the same assays. Results showed no unambiguous clinical late complications of Lyme borreliosis, even in inadequately treated or untreated patients. Seropositivity varied considerably according to the assay used; the indirect immunofluorescence assay yielded the highest scores. The proportion of seropositive results (immunofluorescence assay) was 59% in patients with erythema chronicum migrans, 69% in those with lymphocytoma cutis, and 100% in those with acrodermatitis chronica atrophicans (overall 63%); in contrast, only 31% of the blood donor control group were found to be seropositive. Seropositivity did not correlate with adequacy of treatment, interval between onset of symptoms and treatment, time span since treatment, age of patients, and presence of antinuclear antibodies. Immunoblot pattern showed high incidence of antibodies against the 29/31-kD (outer surface proteins OspA and OspB) and 55/58-kD antigens in general and against the 41-kD protein (flagellin) in patients with acrodermatitis chronica atrophicans only.
authors.affiliation: Department of Dermatology, University of Innsbruck Medical School, Austria.
authors.forename: A
authors.initials: A
authors.lastname: Plörer
authors.forename: N
authors.initials: N
authors.lastname: Sepp
authors.forename: E
authors.initials: E
authors.lastname: Schmutzhard
authors.forename: S
authors.initials: S
authors.lastname: Krabichler
authors.forename: S
authors.initials: S
authors.lastname: Trobos
authors.forename: G
authors.initials: G
authors.lastname: Schauer
authors.forename: C
authors.initials: C
authors.lastname: Pahl
authors.forename: G
authors.initials: G
authors.lastname: Stöffler
authors.forename: P
authors.initials: P
authors.lastname: Fritsch
mesh_terms: D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000888:Antibodies, Anti-Idiotypic / Q000097:blood; D000907:Antibodies, Bacterial; D001898:Borrelia / Q000276:immunology; D005500:Follow-Up Studies; D006801:Humans; D015151:Immunoblotting; D007075:Immunoglobulin M / Q000097:blood; D008193:Lyme Disease / Q000097:blood* / Q000150:complications* / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D017192:Skin Diseases, Bacterial / Q000097:blood / Q000150:complications* / Q000628:therapy*; D013997:Time Factors
chemical_list: D000900:Anti-Bacterial Agents; D000888:Antibodies, Anti-Idiotypic; D000907:Antibodies, Bacterial; D007075:Immunoglobulin M; C044203:anti-IgM